Protein Biomarker in Hepatocellular Carcinoma
Protein Biomarkers for Early Detection and Prognostication in Hepatocellular Carcinoma (HCC)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Terminated
Loss of funding due to difficulty with recruitment and participant retention.
Other terminated trials from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Oligometastatic Disease · Apr 2026
- Systemic Sclerosis · Phase PHASE1 · Nov 2024
- Renal Cell Carcinoma Metastatic · Phase NA · Apr 2024
- Pancreas Cancer · Phase NA · Aug 2023
- Glioma, Malignant · Aug 2022
See all terminations from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Listed as NCT00465842, this observational or N/A phase trial focuses on Hepatitis and Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Mar 2019 — Jan 2021 [monthly]
Terminated
Status: Suspended → Terminated
-
Jun 2018 — Mar 2019 [monthly]
Suspended
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Suspended
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Suspended NA
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Singapore Cancer Society
For direct contact, visit the study record on ClinicalTrials.gov .